세계의 면역 종양 진단 시장 - 경영진/컨설턴트 가이드와 커스터마이즈 예측 및 분석 (2025-2029년) - 인공지능(AI)의 영향

Market Forecasts for Immuno-Oncology Diagnostics. Including Executive/Consultant Guides and Customized Forecasting/Analysis. 2025 to 2029. Including Impact of Aritificial Intelligence

US $ 6,995 ￦ 9,728,000

PDF (Single User License)

PDF 보고서를 1명(One device)만 이용할 수 있는 라이선스입니다. 인쇄 불가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 10,495 ￦ 14,596,000

PDF (Five User License)

PDF 보고서를 동일 사업장의 5명(Five devices)까지 이용할 수 있는 라이선스입니다. 인쇄 불가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 13,995 ￦ 19,464,000

PDF (Enterprise License)

PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄는 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

한글목차

진단약, 동반진단약이 면역종양학 치료제의 성공을 견인하고 있습니다. 진단약 산업은 완전히 새로운 부문을 창출하고 있습니다. 그것도 작은 분야가 아닙니다. 비약적인 성장이 약속되어 있습니다. 조직학, 유전체학, 액체생검이 융합되고 있습니다. 제약회사, 진단회사, 장비 공급업체의 복잡한 네트워크가 암을 극복하기 위한 새로운 접근법을 모색하고 있습니다. 이 접근법은 잘 작동하고 있으며, 큰 잠재력을 보여주고 있습니다.

암 치료의 혁명이 진행 중입니다. 신체의 자연 면역 방어력을 이용한 새로운 치료법은 전례 없는 성공을 거두고 있습니다. 그러나 적절한 치료법을 선택하기 위한 진단법, 특히 바이오마커가 절실히 요구되고 있습니다.

기술의 발전은 시장보다 빠릅니다. 의료산업에 미치는 영향은 엄청납니다. 종양 돌연변이 부하, 체크포인트 억제제, 사이토카인 등의 전문용어를 알기 쉽게 설명합니다.

세계의 면역 종양 진단 시장에 대해 조사했으며, 시장 개요와 함께 용도별/기술별/고객별 동향, 시장 진출기업 프로파일 등의 정보를 전해드립니다.

목차

제1장 시장 가이드

• 상황 분석
• 경영 임원과 마케팅 담당자를 위한 가이드
• 투자 애널리스트와 경영 컨설턴트를 위한 가이드
• 인공지능(AI)의 영향

제2장 서론과 시장의 정의

• 면역 종양 진단이란 무엇인가
• 면역 종양학 - 다가오는 치료법
• 시장 정의
• 조사 방법
• 시점 : 헬스케어와 IVD 업계

제3장 면역치료-면역 기술 가이드

• 면역 시스템
  • 선천성 면역 시스템
  • 적응 면역 시스템
  • 종양 면역학-면역 감시 시스템
• 면역 종양 진단
  • 체크포인트 어세이
  • 사이토카인 어세이
  • 유전체 생식 세포 계열
  • 유전체 종양
  • 종양 미세환경
  • 기타

제4장 업계 개요

• 시장 참여 조직
  • 학술연구기관
  • 진단 시험 개발자
  • 계측 기기 공급업체
  • 약품 및 시약 제조업체
  • 병리 공급업체
  • 독립계 임상 실험실
  • 공공 국립 및 지역 연구소
  • 병원 검사실
  • 임상 실험실
  • 감사기관
  • 인증기관

제5장 시장 동향

• 성장 촉진요인
• 성장 억제요인
• 진단 기술 개발

제6장 암면역 종양 진단의 최근 동향

제7장 주요 면역 종양학 기업 개요

• 10x Genomics, Inc.
• Abbott Laboratories
• AccuraGen Inc.
• Adaptive Biotechnologies
• Aethlon Medical
• Agilent
• Anchor Dx
• ANGLE plc
• ARUP Laboratories
• AVIVA Systems Biology
• Baylor Miraca Genetics Laboratories
• Beckman Coulter Diagnostics(Danaher)
• Becton, Dickinson and Company
• Berkley Lights
• BGI Genomics Co. Ltd
• Bioarray Genetics
• Biocartis
• Biocept, Inc.
• Biodesix Inc.
• BioFluidica
• BioGenex
• BioIVT
• Biolidics Ltd
• bioMerieux Diagnostics
• Bioneer Corporation
• Bio-Rad Laboratories, Inc.
• Bio-Reference Laboratories
• Bio-Techne
• Bioview
• Bristol-Myers Squibb
• Burning Rock
• Cardiff Oncology
• Caris Molecular Diagnostics
• Castle Biosciences, Inc.
• CellCarta
• CellMax Life
• Cepheid(Danaher)
• Charles River Laboratories
• Circulogene
• Cizzle Biotech
• Clearbridge Biomedics
• Clinical Genomics
• Cytolumina Technologies Corp.
• Datar Cancer Genetics Limited
• Diagnologix LLC
• Diasorin S.p.A.
• Dxcover
• Element Biosciences
• Enzo Biochem
• Epic Sciences
• Epigenomics AG
• Eurofins Scientific
• Fabric Genomics
• Fluxion Biosciences(Cell Microsystems)
• Freenome
• FUJIFILM Wako Diagnostics
• Fujirebio
• Fyr Diagnostics
• GeneFirst Ltd.
• Genetron Holdings
• GenomOncology
• GILUPI Nanomedizin
• Guardant Health
• HansaBiomed
• HTG Molecular Diagnostics
• iCellate
• ICON PLC
• Illumina
• Incell Dx
• Inivata
• INOVIQ
• Invitae Corporation
• Invivogen
• Invivoscribe
• J&J Innovative Medicine
• KEW
• Lucence Health
• Lunglife AI Inc
• MDNA Life SCIENCES, Inc.
• MDx Health
• Menarini Silicon Biosystems
• Mesa Laboratories, Inc.
• Millipore Sigma
• Miltenyi Biotec
• miR Scientific
• Myriad Genetics
• Nanostring
• NantHealth, Inc.
• Natera
• NeoGenomics
• NGeneBio
• Novogene
• Oncimmune
• Oncocyte
• OncoDNA
• Oncohost
• Oxford Nanopore Technologies
• PamGene
• Panagene
• Personalis
• PGDx(Labcorp)
• Precipio
• PrecisionMed
• Predicine
• Predictive Oncology
• Prenetics
• Promega
• Qiagen
• QuidelOrtho
• Rarecells SAS
• RareCyte
• Recursion Pharma
• Revvity
• Roche Diagnostics
• Screencell
• Sherlock Biosciences
• Siemens Healthineers
• simfo GmbH
• Singlera Genomics Inc.
• Singular Genomics
• Singulomics
• SkylineDx
• Standard BioTools
• Stilla Technologies
• Sysmex Inostics
• Tempus Labs, Inc.
• Thermo Fisher Scientific
• Todos Medical
• Ultima Genomics
• Veracyte
• VolitionRX
• Vortex Biosciences

제8장 세계의 면역 종양 진단 시장

• 국가별 세계 시장 개요
• 어세이 유형별 세계 시장 - 개요
• 기술별 세계 시장 - 개요
• 고객별 세계 시장 - 개요

제9장 세계의 면역 종양 진단 시장 - 용도별

• 체크포인트
• 사이토카인
• 생식세포 유전학
• 유전성 종양
• 종양 미세환경
• 기타

제10장 세계의 면역 종양 진단 시장 - 기술별

• NGS
• PCR
• FISH/IHC
• Chem/IA
• 기타

제11장 세계의 면역 종양 진단 시장 - 고객별

• 제약
• 클리닉
• 기타

제12장 부록

LSH

영문 목차

영문목차

OVERVIEW:

Diagnostics, companion diagnostics, is driving the success of Immuno-oncology Therapeutics. An entire new segment of the diagnostics industry is being created. And its not a small segment either. It promises to grow dramatically. Histology, genomics and liquid biopsy are converging. A complicated network of pharmaceutical companies, diagnostic companies and instrumentation suppliers are jockeying for position in a new approach to conquering cancer. The approach seems to be working and showing great promise.

A revolution in cancer therapy is underway. New therapy based on using the body's natural immune defenses is having unprecedented success. But diagnostics, especially biomarkers are desperately needed to help select the right therapy.

The technology is moving faster than the market. The impact on the health care industry is enormous. Tumor Mutational Burden? Checkpoint Inhibitors? Cytokines? Find out about the technology in readily understood terms that explain the jargon. Find the opportunities and the pitfalls. Understand growth expectations and the ultimate potential market size in this new expanded and comprehensive report.

Table of Contents

1. Market Guides

• 1.1. Situation Analysis
• 1.2. Guide for Executives and Marketing Staff
• 1.3. Guide for Investment Analysts and Management Consultants
• 1.4. Impact of Artificial Intelligence

2. Introduction and Market Definition

• 2.1. What are Immuno-Oncology Diagnostics?
• 2.2. Immuno-oncology - the looming cure
  • 2.2.1. Immuno-oncology Diagnostics Takes a Leading Role
• 2.3. Market Definition
  • 2.3.1. Market Size
  • 2.3.2. Currency
  • 2.3.3. Years
• 2.4. Methodology
  • 2.4.1. Methodology
  • 2.4.2. Sources
  • 2.4.3. Authors
• 2.5. Perspective: Healthcare and the IVD Industry
  • 2.5.1. Global Healthcare Spending
  • 2.5.2. Spending on Diagnostics
  • 2.5.3. Important Role of Insurance for Diagnostics

3. Immunotherapy - Guide to Immune Technologies

• 3.1. The Immune System
  • 3.1.1. Innate immune system
    • 3.1.1.1. Surface barriers
    • 3.1.1.2. Inflammation
    • 3.1.1.3. Complement system
    • 3.1.1.4. Cellular barriers
    • 3.1.1.5. Natural killer cells
  • 3.1.2. Adaptive immune system
    • 3.1.2.1. Lymphocytes
    • 3.1.2.2. Killer T cells
    • 3.1.2.3. Helper T cells
    • 3.1.2.4. Gamma delta T cells
    • 3.1.2.5. B lymphocytes and antibodies
  • 3.1.3. Tumor immunology - the immune surveillance system
• 3.2. Immuno Oncology Diagnostics
  • 3.2.1. Checkpoint Assays
    • 3.2.1.1. Outlook for Checkpoint Assays
  • 3.2.2. Cytokine Assays
    • 3.2.2.1. Outlook for Cytokine Assays
  • 3.2.3. Genomic Germline
    • 3.2.3.1. Outlook for Genomic Germline
  • 3.2.4. Genomic Tumour
    • 3.2.4.1. Outlook for Genomic Tumour
  • 3.2.5. Tumor Microenviroment
    • 3.2.5.1. Outlook for Tumor Microenvironment
  • 3.2.6. Others
    • 3.2.6.1. Outlook for Other Diagnostics

4. Industry Overview

• 4.1. Players in a Dynamic Market
  • 4.1.1. Academic Research Lab
  • 4.1.2. Diagnostic Test Developer
  • 4.1.3. Instrumentation Supplier
  • 4.1.4. Chemical/Reagent Supplier
  • 4.1.5. Pathology Supplier
  • 4.1.6. Independent Clinical Laboratory
  • 4.1.7. Public National/regional Laboratory
  • 4.1.8. Hospital Laboratory
  • 4.1.9. Physicians Office Lab (POLS)
  • 4.1.10. Audit Body
  • 4.1.11. Certification Body

5. Market Trends

• 5.1. Factors Driving Growth
  • 5.1.1. Outcome potential
  • 5.1.2. Companion Diagnostics
  • 5.1.3. Funding
  • 5.1.4. Technology Environment
  • 5.1.5. Target Solutions
• 5.2. Factors Limiting Growth
  • 5.2.1. Complex Role of Diagnostics
  • 5.2.2. Clinical Trials Role
  • 5.2.3. Protocols
• 5.3. Diagnostic Technology Development
  • 5.3.1. Combinations - Issues and Complexity
  • 5.3.2. Shifting Role of Diagnostics
  • 5.3.3. Multiplexing and Foundation One
  • 5.3.4. The Disruption Dynamic
  • 5.3.5. The Race for Biomarkers
  • 5.3.6. The Next Five Years

6. Cancer Immuno-Oncology Diagnostics Recent Developments

• 6.1. Recent Developments - Importance and How to Use This Section
  • 6.1.1. Importance of These Developments
  • 6.1.2. How to Use This Section
• 6.2. Personalis Outlook Positive
• 6.3. Agilent Technologies Expands Certification for PD-L1 CDx
• 6.4. Foundation Medicine, Sumitomo Pharma to Develop CDx
• 6.5. Erisyon to Develop Diagnostic for Immuno-Oncology
• 6.6. Caris Life Sciences Expands CDx
• 6.7. FDA approves Illumina cancer biomarker test
• 6.8. Tempus Expands Immuno-Oncology Portfolio with AI
• 6.9. Foundation Medicine, Repare to Partner on CDx for Lunresertib
• 6.10. Thermo Fisher and Bayer to Develop CDx for Cancer Therapies
• 6.11. ClearNote Health Expands Into Immunotherapy Monitoring
• 6.12. Foundation Medicine to Collaborate on CDx for Lung Cancer
• 6.13. Qiagen and Myriad Genetics Partner to Develop Cancer CDx
• 6.14. Lung Cancer Data Heralds Shift for Hummingbird Dx
• 6.15. PamGene Awarded Euro-7.5M for Immunotherapy Test
• 6.16. Freenome Acquires Oncimmune
• 6.17. Guardant Health Gets Coverage for Liquid Biopsy Treatment Response Test
• 6.18. BostonGene to Develop Sarcoma-Specific Liquid Biopsy
• 6.19. Exact Sciences OncoExTra Therapy Selection Test
• 6.20. Integrated DNA Technologies Buys NGS Research Assays
• 6.21. Navignostics Using Single-Cell Spatial Proteomics
• 6.22. New Reference Samples for NGS-Based Cancer Tests
• 6.23. Spatial Proteomics Panel for Immuno-Oncology
• 6.24. dMMR, MSI Assays for Immunotherapy Patient Selection
• 6.25. OncoHost Expands Prophet Platform Research
• 6.26. Protein-Based Liquid Biopsy Panel Assesses TME

7. Profiles of Key Immuno-oncology Companies

• 7.1. 10x Genomics, Inc.
• 7.2. Abbott Laboratories
• 7.3. AccuraGen Inc.
• 7.4. Adaptive Biotechnologies
• 7.5. Aethlon Medical
• 7.6. Agilent
• 7.7. Anchor Dx
• 7.8. ANGLE plc
• 7.9. ARUP Laboratories
• 7.10. AVIVA Systems Biology
• 7.11. Baylor Miraca Genetics Laboratories
• 7.12. Beckman Coulter Diagnostics (Danaher)
• 7.13. Becton, Dickinson and Company
• 7.14. Berkley Lights
• 7.15. BGI Genomics Co. Ltd
• 7.16. Bioarray Genetics
• 7.17. Biocartis
• 7.18. Biocept, Inc.
• 7.19. Biodesix Inc.
• 7.20. BioFluidica
• 7.21. BioGenex
• 7.22. BioIVT
• 7.23. Biolidics Ltd
• 7.24. bioMerieux Diagnostics
• 7.25. Bioneer Corporation
• 7.26. Bio-Rad Laboratories, Inc.
• 7.27. Bio-Reference Laboratories
• 7.28. Bio-Techne
• 7.29. Bioview
• 7.30. Bristol-Myers Squibb
• 7.31. Burning Rock
• 7.32. Cardiff Oncology
• 7.33. Caris Molecular Diagnostics
• 7.34. Castle Biosciences, Inc.
• 7.35. CellCarta
• 7.36. CellMax Life
• 7.37. Cepheid (Danaher)
• 7.38. Charles River Laboratories
• 7.39. Circulogene
• 7.40. Cizzle Biotech
• 7.41. Clearbridge Biomedics
• 7.42. Clinical Genomics
• 7.43. Cytolumina Technologies Corp.
• 7.44. Datar Cancer Genetics Limited
• 7.45. Diagnologix LLC
• 7.46. Diasorin S.p.A.
• 7.47. Dxcover
• 7.48. Element Biosciences
• 7.49. Enzo Biochem
• 7.50. Epic Sciences
• 7.51. Epigenomics AG
• 7.52. Eurofins Scientific
• 7.53. Fabric Genomics
• 7.54. Fluxion Biosciences (Cell Microsystems)
• 7.55. Freenome
• 7.56. FUJIFILM Wako Diagnostics
• 7.57. Fujirebio
• 7.58. Fyr Diagnostics
• 7.59. GeneFirst Ltd.
• 7.60. Genetron Holdings
• 7.61. GenomOncology
• 7.62. GILUPI Nanomedizin
• 7.63. Guardant Health
• 7.64. HansaBiomed
• 7.65. HTG Molecular Diagnostics
• 7.66. iCellate
• 7.67. ICON PLC
• 7.68. Illumina
• 7.69. Incell Dx
• 7.70. Inivata
• 7.71. INOVIQ
• 7.72. Invitae Corporation
• 7.73. Invivogen
• 7.74. Invivoscribe
• 7.75. J&J Innovative Medicine
• 7.76. KEW
• 7.77. Lucence Health
• 7.78. Lunglife AI Inc
• 7.79. MDNA Life SCIENCES, Inc.
• 7.80. MDx Health
• 7.81. Menarini Silicon Biosystems
• 7.82. Mesa Laboratories, Inc.
• 7.83. Millipore Sigma
• 7.84. Miltenyi Biotec
• 7.85. miR Scientific
• 7.86. Myriad Genetics
• 7.87. Nanostring
• 7.88. NantHealth, Inc.
• 7.89. Natera
• 7.90. NeoGenomics
• 7.91. NGeneBio
• 7.92. Novogene
• 7.93. Oncimmune
• 7.94. Oncocyte
• 7.95. OncoDNA
• 7.96. Oncohost
• 7.97. Oxford Nanopore Technologies
• 7.98. PamGene
• 7.99. Panagene
• 7.100. Personalis
• 7.101. PGDx (Labcorp)
• 7.102. Precipio
• 7.103. PrecisionMed
• 7.104. Predicine
• 7.105. Predictive Oncology
• 7.106. Prenetics
• 7.107. Promega
• 7.108. Qiagen
• 7.109. QuidelOrtho
• 7.110. Rarecells SAS
• 7.111. RareCyte
• 7.112. Recursion Pharma
• 7.113. Revvity
• 7.114. Roche Diagnostics
• 7.115. Screencell
• 7.116. Sherlock Biosciences
• 7.117. Siemens Healthineers
• 7.118. simfo GmbH
• 7.119. Singlera Genomics Inc.
• 7.120. Singular Genomics
• 7.121. Singulomics
• 7.122. SkylineDx
• 7.123. Standard BioTools
• 7.124. Stilla Technologies
• 7.125. Sysmex Inostics
• 7.126. Tempus Labs, Inc.
• 7.127. Thermo Fisher Scientific
• 7.128. Todos Medical
• 7.129. Ultima Genomics
• 7.130. Veracyte
• 7.131. VolitionRX
• 7.132. Vortex Biosciences

8. The Global Market for Immuno-Oncology Diagnostics

• 8.1. Global Market Overview by Country
  • 8.1.1. Table - Global Market by Country
  • 8.1.2. Chart - Global Market by Country
• 8.2. Global Market by Assay Type - Overview
  • 8.2.1. Table - Global Market by Assay Type
  • 8.2.2. Chart - Global Market by Assay Type - Base/Final Year Comparison
  • 8.2.3. Chart - Global Market by Assay Type - Base Year
  • 8.2.4. Chart - Global Market by Assay Type - End Year
  • 8.2.5. Chart - Global Market by Assay Type - Share by Year
  • 8.2.6. Chart - Global Market by Assay Type - Segments Growth
• 8.3. Global Market by Technology - Overview
  • 8.3.1. Table - Global Market by Technology
  • 8.3.2. Chart - Global Market by Technology - Base/Final Year Comparison
  • 8.3.3. Chart - Global Market by Technology - Base Year
  • 8.3.4. Chart - Global Market by Technology - End Year
  • 8.3.5. Chart - Global Market by Technology - Share by Year
  • 8.3.6. Chart - Global Market by Technology - Segments Growth
• 8.4. Global Market by Customer - Overview
  • 8.4.1. Table - Global Market by Customer
  • 8.4.2. Chart - Global Market by Customer - Base/Final Year Comparison
  • 8.4.3. Chart - Global Market by Customer - Base Year
  • 8.4.4. Chart - Global Market by Customer - End Year
  • 8.4.5. Chart - Global Market by Customer - Share by Year
  • 8.4.6. Chart - Global Market by Customer - Segments Growth

9. Global Immuno-Oncology Diagnostic Markets - By Application

• 9.1. Checkpoint
  • 9.1.1. Table Checkpoint - by Country
  • 9.1.2. Chart - Checkpoint Growth
• 9.2. Cytokine
  • 9.2.1. Table Cytokine - by Country
  • 9.2.2. Chart - Cytokine Growth
• 9.3. Germline Genetic
  • 9.3.1. Table Germline Genetic - by Country
  • 9.3.2. Chart - Germline Genetic Growth
• 9.4. Genetic Tumor
  • 9.4.1. Table Genetic Tumor - by Country
  • 9.4.2. Chart - Genetic Tumor Growth
• 9.5. Tumor Microenvironment
  • 9.5.1. Table Tumor Microenvironment - by Country
  • 9.5.2. Chart - Tumor Microenvironment Growth
• 9.6. Other
  • 9.6.1. Table Other - by Country
  • 9.6.2. Chart - Other Growth

10. Global Immuno-Oncology Diagnostic Markets - By Technology

• 10.1. NGS
  • 10.1.1. Table NGS - by Country
  • 10.1.2. Chart - NGS Growth
• 10.2. PCR
  • 10.2.1. Table PCR - by Country
  • 10.2.2. Chart - PCR Growth
• 10.3. Fish/IHC
  • 10.3.1. Table Fish/IHC - by Country
  • 10.3.2. Chart - Fish/IHC Growth
• 10.4. Chem/IA
  • 10.4.1. Table Chem/IA - by Country
  • 10.4.2. Chart - Chem/IA Growth
• 10.5. Other Technology
  • 10.5.1. Table Other Technology - by Country
  • 10.5.2. Chart - Other Technology Growth

11. Global Immuno-Oncology Diagnostic Markets - By Customer

• 11.1. Pharma
  • 11.1.1. Table Pharma - by Country
  • 11.1.2. Chart - Pharma Growth
• 11.2. Clinic
  • 11.2.1. Table Clinic - by Country
  • 11.2.2. Chart - Clinic Growth
• 11.3. Other Customer Genetic
  • 11.3.1. Table Other Customer - by Country
  • 11.3.2. Chart - Other Customer Growth

12. Appendices

• 12.1. Prevalence of Cancer Treatments
• 12.2. Growth of Approved IVD Test Menu
• 12.3. Growth of Approved Average IVD Test Fee
• 12.4. The Most Used IVD Assays
• 12.5. The Highest Grossing Assays
• 12.6. Laboratory Fees Schedule

관련자료